The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to Infliximab
Not Applicable
- Conditions
- Crohn's Disease patient as following 1)or 2) 1)the patient who treated with IFX infusion of interval every 4-6 weeks. 2)the patient who could not keep to treat with IFX due to side effect or ineffectiveness.
- Registration Number
- JPRN-UMIN000005761
- Lead Sponsor
- Kenji Watanabe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)The patient of contraindication for adalimumab as following a.serious infections b.active tuberculosis c.hypersensitivity d.neurologic reactions (peripheral demyelinating disease) e.congestive heart failure 2)The case which is hard to get the patient's consent 3)The patient who was judged for unsuitable by responsibility doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method